Table 2. Multivariable Predictors of Early LVEF Improvement (Increase of ≥10% Points) After TAVR.
| Characteristic | Full model | Parsimonious model | ||
|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Age | 1.00 (0.97-1.03) | .98 | NA | NA |
| Male | 0.98 (0.53-1.83) | .96 | NA | NA |
| BMI | 1.06 (1.02-1.10) | .005 | 1.06 (1.02-1.10) | <.001 |
| STS score | 0.99 (0.93-1.05) | .67 | NA | NA |
| NYHA class III/IV | 1.59 (0.83-3.04) | .16 | NA | NA |
| Hypertension | 0.73 (0.37-1.42) | .35 | NA | NA |
| Diabetes | 0.55 (0.34-0.86) | .01 | 0.61 (0.40-0.92) | .02 |
| Coronary artery disease | 1.20 (0.69-2.07) | .52 | NA | NA |
| Prior MI | 0.64 (0.40-1.04) | .07 | 0.65 (0.42-0.98) | .04 |
| Prior PCI | 1.49 (0.93-2.36) | .09 | NA | NA |
| Prior CABG | 0.76 (0.46-1.24) | .27 | NA | NA |
| Prior BAV | 0.57 (0.31-1.05) | .07 | NA | NA |
| Cerebrovascular disease | 1.08 (0.54-2.18) | .83 | NA | NA |
| Peripheral artery disease | 0.78 (0.49-1.24) | .30 | NA | NA |
| Chronic kidney diseasea | 0.80 (0.43-1.49) | .48 | NA | NA |
| COPD | 1.22 (0.77-1.94) | .41 | NA | NA |
| Oxygen-dependent lung disease | 2.03 (0.69-5.98) | .20 | NA | NA |
| Cancer | 0.50 (0.32-0.80) | .003 | 0.56 (0.37-0.86) | .008 |
| Hemoglobin, g/dL | 0.97 (0.86-1.09) | .63 | NA | NA |
| Baseline LVEF, % | 0.93 (0.90-0.96) | <.001 | 0.93 (0.90-0.95) | <.001 |
| LV mass index, g/m2 | 1.00 (1.00-1.01) | .72 | NA | NA |
| LVEDD, cm | 0.61 (0.43-0.87) | .006 | 0.59 (0.44-0.78) | <.001 |
| AV area, cm2 | 0.16 (0.03-0.78) | .02 | 0.19 (0.05-0.73) | .02 |
| LVOT Doppler stroke volume index | 1.02 (0.99-1.06) | .20 | 1.03 (1.00-1.06) | .04 |
| ≥Moderate AR | 0.96 (0.49-1.86) | .90 | NA | NA |
| ≥Moderate MR | 0.80 (0.50-1.28) | .34 | NA | NA |
| Discharge medication | ||||
| β-Blocker | 0.96 (0.60-1.54) | .87 | NA | NA |
| ACE inhibitor/ARB | 1.05 (0.70-1.58) | .81 | NA | NA |
| Procedural complications (≤7 d) | 1.18 (0.69-2.00) | .55 | NA | NA |
| Post-TAVR AV mean gradient | 1.05 (0.98-1.11) | .15 | NA | NA |
| Severe prosthesis-patient mismatch | 0.52 (0.27-1.01) | .054 | 0.59 (0.32-1.07) | .08 |
| Valve type (SAPIEN 3 vs SAPIEN/SAPIEN XT) | 0.66 (0.41-1.08) | .10 | NA | NA |
| Valve size | 0.94 (0.83-1.07) | .37 | 0.91 (0.83-1.01) | .07 |
Abbreviations: ACE, angiotensin-converting enzyme; AR, aortic regurgitation; ARB, angiotensin II receptor blocker; AV, aortic valve; BAV, balloon aortic valvuloplasty; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; LV, left ventricular; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; MI, myocardial infarction; MR, mitral regurgitation; NA, not applicable; NYHA, New York Heart Association; OR, odds ratio; PCI, percutaneous coronary intervention; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement.
SI conversion factors: To convert creatinine to micromoles per liter, multiply by 88.4; hemoglobin to grams per liter, multiply by 10.
Serum creatinine >2 mg/dL.